KNG1 and angioedema: It is established now that sacubitril not only suppresses NEP, but also likely increases bradykinin level, thereby increasing the risk for inflammatory processes via activation of bradykinin 1 (B1) receptors, as well as development of angioedema in animal experimental models [32,33,68].